Received Jun 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | Z9214 | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | — | — |
Menveo extra dose administration; Menveo extra dose administration; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 16-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number Z9214, expiry date 21-JAN-2026) for prophylaxis. Co-suspect products included Men ACWY-CRM NVS (Menveo) for prophylaxis. Previously administered products included Menveo (received first dose on 03-APR-2019). On 19-MAR-2025, the patient received the 3rd dose of Menveo. On 27-SEP-2023, the patient received the 2nd dose of Menveo. On 27-SEP-2023, not applicable after receiving Menveo and an unknown time after receiving Menveo, the patient experienced extra dose administered (Verbatim: Menveo extra dose administration). On 19-MAR-2025, the patient experienced extra dose administered (Verbatim: Menveo extra dose administration). The outcome of the extra dose administered and extra dose administered were not applicable. Additional Information: GSK receipt date: 29-MAY-2025 Clinic supervisor wanted to know how to proceed after a patient received an extra dose of Menveo (1 vial). The patient received three doses in total and given that the patient was already within the 2 to 55 years-old range of age for 1 dose only administration, in reality received two extradoses (one given intentionally and the other inadvertently), which led to extra dose administered. The vaccine administration facility was the same as primary reporter. Only one lot number and expiration date provided (for the third dose).